Salarius Pharmaceuticals, Inc. Gains 59.15%
Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ) soared at $2.44, a gain of 59.2%. On Thu, Jul 18, 2024, SLRX:NASDAQ hit a New 2-Week Intraday High of $2.92. From Fri, Jul 05, 2024, the stock recorded 44.44% Up Days and 40.00% Green Days
About Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ)
Flex Pharma Inc is a US-based biotechnology company which is engaged in the developing proprietary treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The lead drug product candidate is FLX-787 which is a single molecule, chemically synthesized, TRP ion channel activator and HOTSHOT, which is developed to prevent and treat exercise-associated muscle cramps. It operates through two segments - Consumer Operations and Drug Development. The Consumer Operations segment includes the development of HOTSHOT whereas the Drug Development segment includes the development of proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions.
Top 10 Gainers:
- Tempo Automation Holdings Inc. (TMPO:NASDAQ), 84.62%
- Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ), 59.15%
- Arrowroot Acquisition Corp. (ARRW:NASDAQ), 54.64%
- Naas Technology Inc. (NAAS:NASDAQ), 52.93%
- Chuy's Holdings, Inc. (CHUY:NASDAQ), 47.76%
- Onconetix Inc Com (ONCO:NASDAQ), 46.51%
- JE Cleantech Holdings Limited (JCSE:NASDAQ), 43.46%
- Neonode Inc. (NEON:NASDAQ), 39.74%
- Inspire Veterinary Partners Inc. (IVP:NASDAQ), 32.02%
- Lottery.com Inc. (LTRY:NASDAQ), 26.57%